(Bloomberg) -- The 25 people in Roche Holding AG’s obesity pill study would barely be enough to field both sides of a soccer match. Yet their weight loss added $16.8 billion to the Swiss drugmaker’s market value in a day, only the latest in a series of big share moves based on success in tiny trials.Most Read from BloombergHarris Has Enough Delegates to Clinch Nomination for PresidentTrump Risks Getting Tables Turned on Him With New 2024 AdversaryWiz Rejects Google’s $23 Billion Offer, Seeks IPO
(Bloomberg) — The 25 people in Roche Holding AG’s (ROG.SW, RHHBY, RHHVF, RHO6.BE, 0QOK.IL) obesity pill study would barely be enough to field both sides of a soccer match. Yet their weight loss added $16.8 billion to the Swiss drugmaker’s market value in a day, only the latest in a series of big share moves based on success in tiny trials.
(undefined)
View quote details
- undefined (USD)
--(-)
